Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic utility and cutoff differences of NT-proBNP level across subgroups in heart failure with preserved ejection fraction: Insights from the PURSUIT-HFpEF Registry.
Sakamoto D, Sotomi Y, Matsuoka Y, Nakatani D, Okada K, Sunaga A, Kida H, Sato T, Kitamura T, Seo M, Yano M, Hayashi T, Nakagawa A, Nakagawa Y, Tamaki S, Yasumura Y, Yamada T, Hikoso S, Sakata Y; OCVC-Heart Failure Investigator. Sakamoto D, et al. Among authors: sakata y. J Card Fail. 2024 Nov 16:S1071-9164(24)00925-4. doi: 10.1016/j.cardfail.2024.10.440. Online ahead of print. J Card Fail. 2024. PMID: 39557334
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Suzuki K, Yokokawa T, Kawaguchi T, Takada S, Tamaki S, Kawasaki Y, Yamaguchi T, Koizumi K, Matsumoto T, Sakata Y, Arakawa Y, Ayuhara H, Hosonaga M, Yamaguchi M, Tsuji D. Suzuki K, et al. Among authors: sakata y. Sci Rep. 2024 Nov 16;14(1):28271. doi: 10.1038/s41598-024-79781-6. Sci Rep. 2024. PMID: 39550497 Free PMC article. Clinical Trial.
Bioprosthetic Valve Positions in Patients With Atrial Fibrillation　- Insights From the BPV-AF Registry.
Obayashi Y, Miyake M, Takegami M, Amano M, Kitai T, Fujita T, Koyama T, Tanaka H, Ando K, Komiya T, Izumo M, Kawai H, Eishi K, Yoshida K, Kimura T, Nawada R, Sakamoto T, Shibata Y, Fukui T, Minatoya K, Tsujita K, Sakata Y, Fukuzawa M, Uehara K, Tamura T, Nishimura K, Furukawa Y, Izumi C; BPV-AF Registry Group. Obayashi Y, et al. Among authors: sakata y. Circ Rep. 2024 Oct 19;6(11):521-528. doi: 10.1253/circrep.CR-24-0110. eCollection 2024 Nov 8. Circ Rep. 2024. PMID: 39525294 Free PMC article.
Predictive Factors of Unexpected Hospitalization within Six Months of Undergoing Percutaneous Coronary Intervention in Patients with Chronic Coronary Disease.
Furukawa T, Mizote I, Shiraki T, Nakamura D, Nishio M, Fukushima N, Kitao T, Yokoi K, Kumada M, Kitagawa M, Nagai K, Kume K, Hirooka K, Nakagawa T, Ohama T, Takahara M, Hikoso S, Sakata Y. Furukawa T, et al. Among authors: sakata y. Intern Med. 2024 Nov 8. doi: 10.2169/internalmedicine.3929-24. Online ahead of print. Intern Med. 2024. PMID: 39523004 Free article.
Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy　- The HORIZON-HCM Study.
Kitaoka H, Ieda M, Ebato M, Kozuma K, Takayama M, Tanno K, Komiyama N, Sakata Y, Maekawa Y, Minami Y, Ogimoto A, Takaya T, Yasuda S, Amiya E, Furukawa Y, Watanabe T, Hiraya D, Miyagoshi H, Kinoshita G, Reedy A, Hegde SM, Florea V, Izumi C. Kitaoka H, et al. Among authors: sakata y. Circ J. 2024 Nov 7. doi: 10.1253/circj.CJ-24-0501. Online ahead of print. Circ J. 2024. PMID: 39505542 Free article.
Clinical and Histopathological Characteristics of Patients With Myocarditis After mRNA COVID-19 Vaccination.
Omori T, Maruyama K, Ohta-Ogo K, Hatakeyama K, Ishibashi-Ueda H, Onoue K, Nagai T, Kato S, Okumura T, Oikawa M, Amiya E, Yoshizawa S, Suzuki T, Goto H, Nakamura K, Fujino T, Moriwaki K, Nakamori S, Anzai T, Sakata Y, Hiroe M, Imanaka-Yoshida K, Dohi K; Comprehensive Biopsy Features and Outcomes in Myocarditis After COVID-19 mRNA Vaccination (COMBAT COVID-19) Study Investigators. Omori T, et al. Among authors: sakata y. Circ J. 2024 Nov 1. doi: 10.1253/circj.CJ-24-0506. Online ahead of print. Circ J. 2024. PMID: 39496392 Free article.
YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. Katayama Y, et al. Among authors: sakata y. Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-1762. Online ahead of print. Clin Cancer Res. 2024. PMID: 39495173
2,162 results